Intervention: Sulindac
Trial phase: Phase 2
ATC code: M01AB02
SMILES: CC1=C(CC(=O)O)c2cc(F)ccc2/C1=C\c1ccc([S+](C)[O-])cc1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 3
Group description: one tablet twice daily

Sulindac: one tablet twice daily
Eligibility criteria:
-INCLUSION CRITERIA

Histologically confirmed colorectal adenocarcinoma with metastatic disease confined to the liver, or limited extrahepatic intra-abdominal disease Note: limited sites of disease include:

porta hepatis lymph node metastases
pelvic lymph node metastases (internal iliac, external iliac or obturator)
Hepatic and intra-abdominal metastases must be measurable by computed tomography (CT), magnetic resonance imaging (MRI) and/or positron emission tomography (PET) scan
Liver disease must be amenable to gross total resection (R0/R1) with adequate functional liver remnant which requires preservation of at least 2 contiguous hepatic segments with adequate inflow, outflow, and biliary drainage with a functional liver remnant (FLR) volume of more than 20% (for healthy liver)
Greater than or equal to 18 years of age.
Must be able to understand and sign the Informed Consent Documentation.
Clinical performance status of Eastern Cooperative Oncology Group (ECOG) less than or equal to 2.
Life expectancy of greater than six months.
Patients of both genders must be willing to practice birth control during and for one week after taking sulindac/placebo.

Hematology:

Absolute neutrophil count greater than 1500/mm^3 without the support of Filgrastim.
Platelet count greater than 75,000/mm^3.
Hemoglobin greater than 8.0 g/dl.

Chemistry:

Serum creatinine less than or equal to 1.5 mg/dl unless the measured creatinine clearance is greater than 60mL/min/1.73m^2.
Total bilirubin less than or equal to 2 mg/dl, except for patients with diagnosis of Gilberts disease or hepatic pedicle obstruction then total bilirubin must be less than or equal to 5 mg/dl.
International normalized ratio (INR) less than or equal to 1.8.

INCLUSION CRITERIA for NORMAL VOLUNTEERS

Age greater than 18
Able to read and understand the informed consent
No self-reported co morbidities of history of cancer

EXCLUSION CRITERIA

Women of child-bearing potential who are pregnant or breast feeding because of the potentially dangerous effects of the chemotherapy on the fetus or infant.
Active systemic infections, coagulation disorders or other major medical illnesses precluding major surgery.
Patients receiving warfarin anticoagulation, who cannot be transferred to other agents, such as low molecular weight heparins, anti-factor Xa (anti-Xa) agents, etc.
Active bleeding disorders
Patients with uncontrolled hypertension (would suggest: systolic blood pressure (SBP)> 155, diastolic blood pressure (DBP)> 90), unstable coronary disease (unstable angina, evidence of congestive heart failure (CHF), or myocardial infarction (MI) within 6-12 months of study)
Childs B or C cirrhosis or with evidence of severe portal hypertension by history, endoscopy, or radiologic studies or with evidence of moderate to severe ascites.

Prior history of gastrointestinal (GI) bleeding unrelated to a cancer diagnosis

Note: Patients who have a normal upper and lower endoscopy may be enrolled at the discretion of the principal investigator (PI).

Renal insufficiency Discretion of principle investigator.